Sukhmandeep Baidwan, MD
Psychiatry · Napa, CANPI 1346695004
Payments from drug & device makers
Across 105 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$688
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$448
- Takeda Pharmaceuticals U.S.A., Inc.$194
- Otsuka America Pharmaceutical, Inc.$168
- Lundbeck LLC$71
- Indivior Inc.$71
- plus $345 from 10 others
What the payments were for
- Food & beverage$1,93998%
- Education$472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 34 | $688 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 31 | $448 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $194 |
| Otsuka America Pharmaceutical, Inc. | 8 | $168 |
| Lundbeck LLC | 3 | $71 |
| Indivior Inc. | 3 | $71 |
| Johnson & Johnson | 3 | $69 |
| Neurocrine Biosciences, Inc. | 2 | $47 |
| Merck | 2 | $46 |
| Eisai Inc. | 2 | $36 |
| Bausch Health US, LLC | 2 | $33 |
| Avanir Pharmaceuticals, Inc. | 2 | $29 |
| Alkermes, Inc. | 1 | $25 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
| Noven Therapeutics, LLC | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
How this compares
$1,986 in reported general payments places this provider in the 80th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 13 | $2,566 |
| Duloxetine Hcl | 14 | $372 |
| Quetiapine Fumarate | 19 | $304 |
| Divalproex Sodium | 12 | $262 |
| Sertraline Hcl | 16 | $96 |
| Donepezil Hcl | 11 | $50 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Napa
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
- Donald AndersonBanning$10.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.